The Biomarker Clinical Phase Outsourcing Services Market Is Projected To Reach $30.4 Billion By 2030

(MENAFN- EIN Presswire)

Biomarker Clinical Phase Outsourcing Services Market Share

The Business Research Company

The Business Research Company's The Biomarker Clinical Phase Outsourcing Services Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, November 6, 2026 /EINPresswire / -- The biomarker clinical phase outsourcing services sector has rapidly expanded, reflecting the increasing complexity and specialization of clinical trials. As personalized medicine and biomarker-driven research gain momentum, this market is poised for remarkable growth in the coming years. Below is an overview of the market's current scale, growth drivers, regional insights, and the factors shaping its future trajectory.

Market Size and Growth Outlook for Biomarker Clinical Phase Outsourcing Services
The market for biomarker clinical phase outsourcing services is experiencing swift growth. It is projected to increase from $11.91 billion in 2025 to $14.62 billion in 2026, registering a compound annual growth rate (CAGR) of 22.7%. This expansion during the recent years has been fueled by the rising complexity of clinical trial designs, increased activity in oncology research, the growth of biomarker-focused drug development, broader translational research initiatives, and expanding collaborations with expert service providers.
Looking ahead, this market is expected to reach $30.4 billion by 2030, growing at a CAGR of 20.1%. The anticipated surge is driven by the growing need for personalized medicine trials, the adoption of AI-powered biomarker analytics, the rise of multi-biomarker clinical studies, increased investments in precision oncology, and heightened regulatory demands for biomarker validation. Key trends include an uptick in outsourcing biomarker-related clinical trial functions, wider application of predictive and prognostic biomarkers, greater use of omics-based biomarker analyses, expansion in companion diagnostics development, and a stronger focus on precision medicine clinical trials.

Download a free sample of the biomarker clinical phase outsourcing services market report:

Understanding Biomarker Clinical Phase Outsourcing Services
Biomarker clinical phase outsourcing services involve contracting specialized companies or institutions to handle specific biomarker-related aspects of clinical trials. Biomarkers serve as measurable biological indicators used to monitor the safety or effectiveness of treatments during medical research and clinical testing processes.

Primary Factors Propelling Growth in Biomarker Clinical Phase Outsourcing Services
The increasing number of clinical trials worldwide is a major factor driving growth in the biomarker clinical phase outsourcing services market. Clinical trials, which test new medical treatments or diagnostic approaches on human subjects, are growing due to advancements in medical science, the rising incidence of chronic diseases, increased funding from public and private sectors, and the need for innovative therapies.
Outsourcing partners often bring specialized expertise in biomarker discovery, validation, and data analysis, which enhances the accuracy and quality of biomarker data collected during trials. For example, as of November 2025, the National Library of Medicine reported that ClinicalTrials lists 558,242 studies covering all 51 U.S. states and 224 countries and territories worldwide. This extensive volume of trials underscores the expanding demand for specialized outsourcing services in the biomarker clinical phase.

View the full biomarker clinical phase outsourcing services market report:

Regional Insights Highlighting Market Distribution in Biomarker Clinical Phase Outsourcing
In 2025, North America held the largest share of the biomarker clinical phase outsourcing services market. The comprehensive market report also covers significant regions including Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a global perspective on regional market dynamics and growth potential.

What's new in our 2026 market reports:
. Market attractiveness scoring and analysis
. Total addressable market (TAM) analysis
. Company scoring matrix graphics and tables
. Excel dashboards
. Market hotspots infographics
. Key technologies and future trends
. Updated graphics and tables

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...

The Business Research Company -

Follow Us On:
. LinkedIn:

Oliver Guirdham
The Business Research Company
+44 7882 955267
...
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

The Biomarker Clinical Phase Outsourcing Services Market is Projected to Reach $30.4 Billion by 2030 News Provided By TBRC Business Research Pvt Ltd. November 06, 2026, 00:30 GMT Share This Article Distribution channels: Business & Economy, Chemical Industry, Companies, Healthcare & Pharmaceuticals Industry, World & Regional

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

MENAFN05112026003118003196ID1111923505